Future oncology (London, England) · 2026
Real-world treatment patterns for metastatic urothelial cancer in 5 European countries: EVEREST 2.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
De Santis Maria, Milloy Neil, Walley Maria, Simpson Amber, Forshaw Cameron, Vuillet Marthe, Strunz-McKendry Torsten, Kim Janet, Thomas Marie-Catherine
Аннотация
INTRODUCTION: Treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) is evolving in Europe. In 2022, ESMO guidelines recommended avelumab as first-line (1L) maintenance for la/mUC in patients who did not progress on platinum-based chemotherapy (PBC) and, in March 2024, recommended enfortumab vedotin (EV) plus pembrolizumab as the preferred 1L therapy. This study assessed treatment patterns for mUC between December 2023-May 2024.
METHODS: Data were drawn from the Adelphi Real World mUC Disease Specific Programme™, a cross-sectional survey of physician-reported data across France, Germany, Italy, Spain, and the United Kingdom.
RESULTS: Physicians (n = 238) reported data for 1622 patients. PBC was the predominant 1L treatment, administered to 74% (1201/1622)) of patients, while 20% (326/1622) received nonchemotherapy monotherapy. Overall, 2% (31/1622) of patients received EV at 1L (monotherapy/combination). Avelumab was administered to 10% (160/1622) of patients as 1L therapy, 14% (234/1622) as maintenance, and 3% (55/1622) as second-line (2L) therapy (monotherapy/combination). At data collection, 19% (302/1622) patients had received 2L treatment, of whom 25% (74/302) received EV monotherapy and 21% (63/302) pembrolizumab monotherapy.
CONCLUSIONS: Consistent with guidelines, adoption of avelumab maintenance was occurring, although its usage remained limited. Low rates of 2L+ therapies highlight the importance of 1L treatment selection.
METHODS: Data were drawn from the Adelphi Real World mUC Disease Specific Programme™, a cross-sectional survey of physician-reported data across France, Germany, Italy, Spain, and the United Kingdom.
RESULTS: Physicians (n = 238) reported data for 1622 patients. PBC was the predominant 1L treatment, administered to 74% (1201/1622)) of patients, while 20% (326/1622) received nonchemotherapy monotherapy. Overall, 2% (31/1622) of patients received EV at 1L (monotherapy/combination). Avelumab was administered to 10% (160/1622) of patients as 1L therapy, 14% (234/1622) as maintenance, and 3% (55/1622) as second-line (2L) therapy (monotherapy/combination). At data collection, 19% (302/1622) patients had received 2L treatment, of whom 25% (74/302) received EV monotherapy and 21% (63/302) pembrolizumab monotherapy.
CONCLUSIONS: Consistent with guidelines, adoption of avelumab maintenance was occurring, although its usage remained limited. Low rates of 2L+ therapies highlight the importance of 1L treatment selection.